DUE DILIGENCE: Shire As Bid Target: Could It Say No To AstraZeneca … - CNNMoney.com
|
DUE DILIGENCE: Shire As Bid Target: Could It Say No To AstraZeneca …
CNNMoney.com - Mar 18, 2008 But as patent protection for Adderall XR wears off, it's been relying on a successor drug, Vyvanse. The launch of Vyvanse has been a rocky one. … |
Find Out More:
Books:
- Pivotal Response Treatments for Autism: Communication, Social, & Academic Development
- Concerta Side Effects
- ADHD Medication
- Ritalin Is Not The Answer: A Drug-Free, Practical Program for Children Diagnosed with ADD or ADHD
- ADHD: Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults
April 17th, 2008
Vyvanse
Leave a Reply